Examining the association between statins and lung cancer incidence in patients with type 2 diabetes mellitus

Journal of the Formosan Medical Association

Volumn 113, Issue 12, 2014, Pages 940-948

  Dong, Yaa Hui ^a   Lin, Jou Wei ^b,c   Wu, Li Chiu ^a   Chen, Chung Yu ^b,c   Chang, Chia Hsuin ^a,b,c   Chen, Kuan Yu ^b,c   Lai, Mei Shu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

3 hydroxy 3 methyl glutaryl CoA; Diabetes mellitus; Lung neoplasms; Smoking; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER RISK; FEMALE; HUMAN; LUNG ADENOCARCINOMA; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RISK ASSESSMENT; SMOKING; TAIWAN; ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; COHORT ANALYSIS; DIABETES MELLITUS, TYPE 2; INCIDENCE; LUNG NEOPLASMS; MIDDLE AGED;

ADENOCARCINOMA; AGED; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; SMOKING; TAIWAN;

EID: 84918775231     PISSN: 09296646     EISSN: 18760821     Source Type: Journal    
DOI: 10.1016/j.jfma.2013.08.002     Document Type: Article

References (34)

1. Mills E.J., Rachlis B., Wu P., Devereaux P.J., Arora P., Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008, 52:1769-1781.
2. Beri A., Sural N., Mahajan S.B. Non-atheroprotective effects of statins: a systematic review. Am J Cardiovasc Drugs 2009, 9:361-370.
3. Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L., Buckley B.M., Cobbe S.M., et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002, 360:1623-1630.
4. Hunt D., Young P., Simes J., Hague W., Mann S., Owensby D., et al. Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: results from the LIPID trial. Ann Intern Med 2001, 134:931-940.
5. Sato S., Ajiki W., Kobayashi T., Awata N., PCS Study Group Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol 2006, 16:201-206.
6. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
7. Khurana V., Bejjanki H.R., Caldito G., Owens M.W. Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 2007, 131:1282-1288.
8. Suissa S., Dell'aniello S., Vahey S., Renoux C. Time-window bias in case-control studies: statins and lung cancer. Epidemiology 2011, 22:228-231.
9. Levesque L.E., Hanley J.A., Kezouh A., Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010, 340:b5087.
10. Setoguchi S., Glynn R.J., Avorn J., Mogun H., Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007, 115:27-33.
11. Daraselia N., Wang Y., Budoff A., Lituev A., Potapova O., Vansant G., et al. Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res 2012, 2:93-103.
12. Kawaguchi T., Matsumura A., Fukai S., Tamura A., Saito R., Zell J.A., et al. Japanese ethnicity compared with Caucasian ethnicity and never-smoking status are independent favorable prognostic factors for overall survival in non-small cell lung cancer: a collaborative epidemiologic study of the National Hospital Organization Study Group for Lung Cancer (NHSGLC) in Japan and a Southern California Regional Cancer Registry databases. J Thorac Oncol 2010, 5:1001-1010.
13. Johnson J.A., Gale E.A. Diabetes, insulin use, and cancer risk: are observational studies part of the solution-or part of the problem?. Diabetes 2010, 59:1129-1131.
14. Kuriki K., Hirose K., Tajima K. Diabetes and cancer risk for all and specific sites among Japanese men and women. Eur J Cancer Prev 2007, 16:83-89.
15. Matikainen N., Kahri J., Taskinen M.R. Reviewing statin therapy in diabetes-towards the best practise. Prim Care Diabetes 2010, 4:9-15.
16. Chang C.H., Lin J.W., Wu L.C., Lai M.S. Angiotensin receptor blockade and risk of cancer in type 2 diabetes mellitus: a nationwide case-control study. J Clin Oncol 2011, 29:3001-3007.
17. Chang C.H., Lin J.W., Wu L.C., Lai M.S., Chuang L.M., Chan K.A. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012, 55:1462-1472.
18. Chang C.H., Lin J.W., Wu L.C., Lai M.S., Chuang L.M. Oral insulin secretagogues, insulin, and cancer risk in type 2 diabetes mellitus. J Clin Endocrinol Metab 2012, 97:E1170-E1175.
19. WHO Collaborating Centre for Drug Statistics Methodology. Defined daily dose: definition and general considerations. Available from [accessed 1.04.13]. http://www.whocc.no/ddd/definition_and_general_considera/.
20. Shih Y.T., Hung Y.T., Chang H.Y. The design, contents, operation and characteristics of the respondents of the 2001 National Health Interview Survey in Taiwan. Taiwan J Public Health 2003, 22:419-430.
21. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006, 15:291-303.
22. Lee P.N., Forey B.A., Coombs K.J. Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer 2012, 12:385.
23. Marelli C., Gunnarsson C., Ross S., Haas S., Stroup D.F., Cload P., et al. Statins and risk of cancer a retrospective cohort analysis of 45,857 matched pairs from an electronic medical records database of 11 million adult Americans. J Am Coll Cardiol 2011, 58:530-537.
24. Jacobs E.J., Newton C.C., Thun M.J., Gapstur S.M. Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res 2011, 71:1763-1771.
25. Browning D.R., Martin R.M. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007, 120:833-843.
26. Taylor M.L., Wells B.J., Smolak M.J. Statins and cancer: a meta-analysis of case-control studies. Eur J Cancer Prev 2008, 17:259-268.
27. Friedman G.D., Flick E.D., Udaltsova N., Chan J., Quesenberry C.P., Habel L.A. Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf 2008, 17:27-36.
28. Farwell W.R., Scranton R.E., Lawler E.V., Lew R.A., Brophy M.T., Fiore L.D., et al. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008, 100:134-139.
29. Boudreau D.M., Yu O., Johnson J. Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf 2010, 9:603-621.
30. Coogan P.F., Rosenberg L., Strom B.L. Statin use and the risk of 10 cancers. Epidemiology 2007, 18:213-219.
31. Cheng M.H., Chiu H.F., Ho S.C., Yang C.Y. Statin use and the risk of female lung cancer: a population-based case-control study. Lung Cancer 2012, 75:275-279.
32. Brookhart M.A., Patrick A.R., Dormuth C., Avorn J., Shrank W., Cadarette S.M., et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol 2007, 166:348-354.
33. Hanai J., Doro N., Sasaki A.T., Kobayashi S., Cantley L.C., Seth P., et al. Inhibition of lung cancer growth: ATP citrate lyase knockdown and statin treatment leads to dual blockade of mitogen-actiated protein kinase (MAPK) and phosphatidylinositol-3- kinase (PI3K)/AKT pathways. J Cell Physiol 2011, 227:1709-1720.
34. Han J.Y., Lee S.H., Yoo N.J., Hyung L.S., Moon Y.J., Yun T., et al. A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer. Clin Cancer Res 2011, 17:1553-1560.